Perimenopause Assessment Panel

The Perimenopause Assessment Panel is a blood test that measures follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, progesterone, and thyroid-stimulating hormone (TSH). These results can provide additional information when menstrual patterns begin to change or symptoms appear during the transition toward menopause.

The panel supports a broader clinical assessment rather than providing a stand-alone diagnosis. Hormone production can vary considerably during perimenopause, both across the menstrual cycle and from one month to another. A result obtained on one day may therefore differ from a later measurement and may not explain every symptom or independently confirm the stage of the menopausal transition.

What the Perimenopause Assessment Panel measures

• FSH: A pituitary hormone that stimulates ovarian follicles. Levels may become more variable and may rise as ovarian function changes.
• LH: A pituitary hormone involved in ovulation and ovarian hormone production. Its concentration can also vary during the transition.
• Estradiol: The main circulating estrogen during the reproductive years. Estradiol may rise and fall unpredictably during perimenopause.
• Progesterone: A hormone produced mainly after ovulation. Lower or variable values may occur when ovulation becomes less regular.
• TSH: A marker used to assess thyroid regulation. Thyroid disorders can produce symptoms that overlap with those associated with perimenopause.

When the panel may be considered

The panel is intended primarily for women around 45 to 50 years of age who have symptoms or menstrual changes that may be associated with perimenopause. These changes may include shorter or longer cycles, skipped periods, altered bleeding, hot flashes, night sweats, sleep problems, mood changes, or reduced tolerance of physical and mental demands.

Other concerns may include fatigue and low energy, poor concentration and brain fog, weight gain and difficulty losing weight, or headaches, migraines, and dizziness. These symptoms are not specific to perimenopause and may also occur with thyroid disorders, anemia, sleep problems, medication effects, metabolic conditions, stress, or other medical issues.

Including TSH helps provide information about thyroid regulation, but the panel does not rule out every possible cause of symptoms. Additional laboratory testing, a gynecologic examination, primary care assessment, or another specialist evaluation may be appropriate depending on the symptom pattern and medical history.

How the testing pathway works

Step 1: Review the cycle and symptoms

Before testing, it is useful to record the first day of the last menstrual period, usual cycle length, recent changes in bleeding, and the symptoms that prompted the assessment. Hormonal contraception, menopausal hormone therapy, thyroid medication, fertility treatment, pregnancy possibility, and other medications should also be reported because they may influence interpretation.

Step 2: Plan the sampling day

If menstrual cycles are still present, the confirmed sampling time is the second, third, or fourth day of the cycle. Day one is the first day of menstrual bleeding. If bleeding is highly irregular or the cycle day cannot be determined, the appropriate sampling time should be clarified before the blood draw.

Step 3: Venous blood collection

A venous blood sample is collected and used to measure FSH, LH, estradiol, progesterone, and TSH. The collection itself usually takes only a few minutes. Temporary pressure, mild discomfort, or a small bruise can occur at the puncture site.

Step 4: Laboratory analysis

The five markers are analyzed separately and reported with the laboratory reference intervals. Reference intervals can depend on the analytical method, menstrual phase, age, and other clinical factors. Results should therefore be interpreted using the intervals shown on the actual report.

Step 5: Interpret the complete pattern

FSH and LH may trend upward as ovarian responsiveness changes, while estradiol and progesterone can vary substantially. TSH is interpreted separately as part of thyroid assessment. No individual value should be viewed in isolation from age, symptoms, menstrual history, medications, and previous findings.

Why one test may not explain all symptoms

Perimenopause is characterized by hormonal variability rather than a single steady decline. Estradiol may be lower during one cycle and higher during another. Ovulation may occur in some months but not in others, affecting progesterone. FSH and LH can also change between measurements.

For this reason, a result within the reference interval does not necessarily exclude perimenopause, while an elevated or reduced result does not independently establish the phase of transition. In women aged 45 or older with typical symptoms and menstrual changes, the clinical history is often central to the assessment. Testing may be more useful when the presentation is unclear, symptoms overlap with another condition, or additional hormonal context is needed for a medical discussion.

How the results may guide the next step

The report may support a conversation about whether the laboratory pattern is consistent with changing ovarian function, whether thyroid regulation requires further assessment, or whether another explanation should be investigated. A clinician may compare the findings with previous results, request repeat or additional tests, or recommend a gynecologic, endocrinologic, or general medical evaluation.

The panel does not determine whether hormone therapy or another treatment is appropriate. Treatment decisions depend on symptoms, bleeding history, medical and family history, current medications, pregnancy potential, cardiovascular and thrombotic risk, breast and gynecologic history, and personal preferences.

Before sending an inquiry, prepare your age, the first day of your most recent period, recent cycle changes, key symptoms, medication and supplement list, use of hormonal contraception or hormone therapy, and any previous hormone or thyroid results. These details can help clarify whether this panel is an appropriate next step and how sampling should be planned.